Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Copay Accumulator-Type Programs Proposed For ACA Exchange Plans

Executive Summary

Annual payment rule for individual and group plans governed by Affordable Care Act proposes excluding drug manufacturer-sponsored copay assistance from out-of-pocket caps and seeks comments on use of reference pricing.

You may also be interested in...



Generic Tiering Requirement, Enhanced Oversight On Chronic Meds Proposed For Marketplace Plans

Commercial health insurance plans governed by the Affordable Care Act would need to modify their formularies for 2024 with policies to avoid discriminatory coverage of four ‘chronic ... high-cost medical conditions’ as well as overpayment for generics, according to CMS proposals.

Humira, Enbrel Face Pricing Pressures From Copay Accumulator Programs

Payer efforts to undercut copay assistance are getting manufacturers’ attention. PhRMA launches ad campaign warning patients that 'middlemen' are 'trying to keep you from reaching your deductible.'

Payers' Latest Attack On Copay Coupons: 'Accumulator' Programs

More payers are implementing programs that block manufacturer copay coupons for specialty drugs from being applied to deductibles and out-of-pocket maximums, exposing members to higher drug costs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS124638

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel